Multiple Myeloma — Expanded Access Programs

• Study on Early and Late Consolidation/Maintenance Therapy for Multiple Myeloma — University of Arkansas
• Phase III Study on the Safety and Effectiveness of BL-8040 and G-CSF for Stem Cell Mobilization in Multiple Myeloma Patients — BioLineRx, Ltd.
• Study Comparing CAR-T Therapy JNJ-68284528 with Standard Treatments for Relapsed Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing JNJ-79635322 with a BCMAxCD3 Antibody for Treating Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing JNJ-79635322 and Teclistamab for Treating Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study on Using Tocilizumab to Prevent Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant — GlaxoSmithKline
• Study on Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab for Patients with Relapsed or Refractory Myeloma Undergoing Stem Cell Transplant — Memorial Sloan Kettering Cancer Center
• Study on Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone for Treating Relapsed or Resistant Multiple Myeloma — Hackensack Meridian Health
• Study on Combination Therapy with Venetoclax, Daratumumab, and Dexamethasone (With and Without Bortezomib) for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — AbbVie
• Study on Dara-RVd and Teclistamab-RVd for People with Multiple Myeloma — Memorial Sloan Kettering Cancer Center
• Study on Daratumumab for Patients with Newly Diagnosed Multiple Myeloma — Memorial Sloan Kettering Cancer Center
• Study on Elotuzumab with Pomalidomide, Bortezomib, and Dexamethasone for Treating Relapsed Multiple Myeloma — Massachusetts General Hospital
• Study on Elranatamab and Cyclophosphamide for Treating Multiple Myeloma — Memorial Sloan Kettering Cancer Center
• Study on Elranatamab for Patients with Relapsed or Refractory Multiple Myeloma — SCRI Development Innovations, LLC
• Study on JNJ-79635322 for Patients with Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study on Lenalidomide and CC-486 with Radiation Therapy for Patients with Plasmacytoma — Memorial Sloan Kettering Cancer Center
• Study on Teclistamab and Talquetamab Combinations with Daratumumab and Lenalidomide for Newly Diagnosed Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing Teclistamab with Daratumumab and Other Treatments for Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study on TNB-383B for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — AbbVie
• Study on Comparing Etentamig and Daratumumab with Standard Treatment for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant — AbbVie
• Study on the Safety and Effects of ABBV-453 Alone or with Other Myeloma Treatments in Adults with Multiple Myeloma — AbbVie
• Study on Etentamig for Treating Multiple Myeloma, Alone or with Other Medications — AbbVie
• Study on the Dose, Safety, and Effectiveness of CC-220 Alone and with Other Treatments for Multiple Myeloma — Celgene
• Study on Mezigdomide and Elranatamab for Treating Relapsed or Hard-to-Treat Multiple Myeloma — Celgene
• Study on the Effectiveness and Safety of Ciltacabtagene Autoleucel — Janssen Research & Development, LLC
• Study on Belantamab Mafodotin with Standard Treatment for Relapsed-Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Cemsidomide and Dexamethasone for Treating Relapsed or Refractory Multiple Myeloma — C4 Therapeutics, Inc.
• Study on the Effects of Elranatamab, Daratumumab, and Lenalidomide Compared to a Standard Treatment in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Pfizer
• Extension Study for Patients Continuing Venetoclax Treatment from Previous Trials — AbbVie
• Study on CAR T-cell Therapy for Patients with Kidney Problems — Northside Hospital, Inc.
• Study on Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone (Car-BiRD) Therapy for Multiple Myeloma — Weill Medical College of Cornell University
• Study Comparing Two Treatment Combinations for Newly Diagnosed Multiple Myeloma — University of Chicago
• Study on Cevostamab with Pomalidomide and Dexamethasone Compared to Standard Treatment for Previously Treated Multiple Myeloma — Hoffmann-La Roche
• Study on Zevor-cel (CT053) for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — CARsgen Therapeutics Co., Ltd.
• Study on Daratumumab, Carfilzomib, Lenalidomide, and Low Dose Dexamethasone for Newly Diagnosed Multiple Myeloma — University of Chicago
• Early Access to Daratumumab Treatment for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Janssen Research & Development, LLC
• Study on Elotuzumab, Iberdomide, and Dexamethasone After Ide-Cel for Relapsed and Refractory Multiple Myeloma — Omar Nadeem, MD
• Study on Elranatamab for Treating Relapsed or Hard-to-Treat Multiple Myeloma — University of California, San Diego
• Study on Using T-Cell Therapy to Improve Outcomes in Newly Diagnosed Myeloma Patients with Minimal Residual Disease — Noffar Bar
• Study on ERd Combination Treatment for Newly Diagnosed Multiple Myeloma — University of Miami
• Study Comparing Two Treatment Combinations for Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Radiation Therapy and Talquetamab for Treating Multiple Myeloma with Extramedullary Disease — City of Hope Medical Center
• Study on Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma — Massachusetts General Hospital
• Karyopharm Expanded Access Program for Selinexor — Karyopharm Therapeutics Inc
• Study on New Drug Combination for Transplant-Eligible Multiple Myeloma Patients — Massachusetts General Hospital
• Study on Lenalidomide and Melphalan for Stem Cell Transplant in Relapsed Multiple Myeloma — Weill Medical College of Cornell University
• Study on Linvoseltamab and Lenalidomide for Deepening Responses in Newly Diagnosed Multiple Myeloma — Dickran Kazandjian, MD
• Long-term Follow-up Study for Patients Treated with Genetically Modified T Cells — Autolus Limited
• Study on Elranatamab for Treating Multiple Myeloma Resistant to Certain Treatments — Pfizer
• Study on Using Elranatamab for Personalized Maintenance After Transplant in Multiple Myeloma Patients — Washington University School of Medicine
• Study on Melphalan, Prednisone, and Thalidomide or Lenalidomide for Newly Diagnosed Multiple Myeloma — National Cancer Institute (NCI)
• Study on Using Mozobil for Stem Cell Transplantation — Thomas Jefferson University
• Study on Nivolumab for Multiple Myeloma Patients After Idecabtagene Vicleucel Treatment — Wake Forest University Health Sciences
• Phase 2 Study on Adaptive Treatment Strategy for Newly Diagnosed Multiple Myeloma Using Daratumumab-Based Therapy — University of Michigan Rogel Cancer Center
• Phase 3 Study of Teclistamab with Lenalidomide or Alone Versus Lenalidomide Alone for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplant — Stichting European Myeloma Network
• Phase II Study of IRD Treatment After Stem Cell Transplant for Multiple Myeloma — Washington University School of Medicine
• Study Comparing Lenalidomide, Bortezomib, and Dexamethasone with or without Stem Cell Transplant in Multiple Myeloma Patients up to Age 65 — Paul Richardson, MD
• Study on Carfilzomib, Lenalidomide, Dexamethasone, and Belantamab Mafodotin for Multiple Myeloma — Wake Forest University Health Sciences
• Study on Daratumumab Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma — Wake Forest University Health Sciences
• Study on Plinabulin and Pegfilgrastim for People with Multiple Myeloma Undergoing Stem Cell Transplant — Memorial Sloan Kettering Cancer Center
• Study Comparing Belantamab Mafodotin to Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Venetoclax with Carfilzomib and Dexamethasone for Treating Relapsed or Hard-to-Treat Multiple Myeloma — AbbVie
• Study on Belantamab Mafodotin and Feladilimab for Treating Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Belantamab Mafodotin and Nirogacestat for Treating Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Belantamab Mafodotin with Nirogacestat, Lenalidomide, and Dexamethasone for Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Subcutaneous Daratumumab, Weekly Carfilzomib, and Dexamethasone for High-Risk Smoldering Multiple Myeloma — National Cancer Institute (NCI)
• Study on Talquetamab and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Multiple Myeloma — Stanford University
• Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma — National Cancer Institute (NCI)
• Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Alone After Stem-Cell Transplant for Multiple Myeloma — University of Chicago
• Study on Total Therapy 3B: An Extension of Total Therapy for Multiple Myeloma — University of Arkansas
• Study on Improving Remission in High-Risk Multiple Myeloma Patients — University of Arkansas
• Phase III Trial for Low Risk Myeloma: Total Therapy 4B — University of Arkansas
• Study on a Slow and Gentle Treatment Approach for Very Frail Patients with Multiple Myeloma Using Isatuximab, Dexamethasone, and Lenalidomide — University of Utah
• Long-term Study for People Previously Treated with Ciltacabtagene Autoleucel — Janssen Research & Development, LLC
• Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone for Multiple Myeloma Patients Previously Treated with Daratumumab — Weill Medical College of Cornell University
• Study Comparing Anitocabtagene Autoleucel to Standard Therapy in Patients with Relapsed or Refractory Multiple Myeloma — Kite, A Gilead Company
• Study Comparing Daratumumab with VELCADE, Lenalidomide, and Dexamethasone (D-VRd) to VELCADE, Lenalidomide, and Dexamethasone (VRd) in Untreated Multiple Myeloma Patients Not Planning Stem Cell Transplant — Janssen Research & Development, LLC
• Study on the Effectiveness and Safety of Cevostamab in Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Hoffmann-La Roche
• Study Comparing Two Treatment Approaches for Newly Diagnosed Multiple Myeloma Without Planned Stem Cell Transplant — Janssen Research & Development, LLC
• Study on Ciltacabtagene Autoleucel and Talquetamab for Treating High-Risk Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing Two Drug Combinations for Previously Treated Multiple Myeloma — Stichting European Myeloma Network
• Study on CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Kidney Disease Related to Monoclonal Gammopathy — Memorial Sloan Kettering Cancer Center
• Study on Daratumumab for Patients with Multiple Myeloma or Smoldering Multiple Myeloma — Janssen Research & Development, LLC
• Study on Daratumumab and Lenalidomide vs. Lenalidomide Alone for Maintenance Treatment in Newly Diagnosed Multiple Myeloma Patients — Janssen Research & Development, LLC
• Study Comparing Two Treatment Approaches for Newly Diagnosed Multiple Myeloma: DVRd with Ciltacabtagene Autoleucel vs. DVRd with Stem Cell Transplant — Stichting European Myeloma Network
• Study on Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly-Diagnosed Multiple Myeloma Patients — University of Miami
• Study on Different Treatment Sequences for Newly Diagnosed Standard-Risk Multiple Myeloma — Janssen Research & Development, LLC
• Study on Quality of Life in People with Multiple Myeloma Receiving Daratumumab or Lenalidomide — Memorial Sloan Kettering Cancer Center
• Study on Ixazomib with Lenalidomide and Dexamethasone for Treating Multiple Myeloma — Takeda
• Study on CAR-T Cell Therapy JNJ-68284528 for Treating Multiple Myeloma — Janssen Research & Development, LLC
• Study on Melphalan With or Without Siltuximab for Multiple Myeloma Patients Undergoing Stem Cell Transplant — Memorial Sloan Kettering Cancer Center
• Study on Selinexor Combined with Carfilzomib, Daratumumab, or Pomalidomide for Multiple Myeloma Patients — Hackensack Meridian Health
• Study on Talquetamab for People with Multiple Myeloma After BCMA CAR T-Cell Therapy — Memorial Sloan Kettering Cancer Center
• Study on the Combination of Talquetamab and Teclistamab for Treating Relapsed or Hard-to-Treat Multiple Myeloma — Janssen Research & Development, LLC
• Study on Whether Ide-cel (bb2121) Can Be Made from People with Multiple Myeloma Who Have Had a Blood Cell Transplant — Memorial Sloan Kettering Cancer Center
• Study Comparing Iberdomide and Lenalidomide Maintenance Therapy After Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients — Bristol-Myers Squibb
• Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy to Lenalidomide Alone in Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant — Celgene
• Study on the Safety, Drug Levels, and Effectiveness of CC-92480 with Other Treatments for Relapsed or Refractory Multiple Myeloma — Bristol-Myers Squibb
• Study on Elranatamab for Treating Multiple Myeloma That Has Returned or Not Responded to Treatment — Pfizer
• Study Comparing Melphalan Alone to a Combination Treatment (BEAM) for Patients with Multiple Myeloma Undergoing High Dose Therapy and Stem Cell Reinfusion — Swedish Medical Center
• Study on Linvoseltamab for Newly Diagnosed Multiple Myeloma Patients Who Have Not Yet Received Treatment — Regeneron Pharmaceuticals
• Study on Using Genetically Modified T-Cells to Target Cancer Mutations in People with Metastatic Cancer — National Cancer Institute (NCI)
• Study on the Effectiveness and Safety of bb2121 for Patients with Relapsed, Refractory, or High-Risk Multiple Myeloma — Celgene
• Study on APG-2575 Combined with New Treatments for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Ascentage Pharma Group Inc.
• At-Home Cancer Treatment Compared to In-Clinic Treatment for Patients with Advanced Cancer — Mayo Clinic
• Study on ATRA and Carfilzomib for Patients with Multiple Myeloma — The Methodist Hospital Research Institute
• Study on AZD0305 Alone or with Other Cancer Drugs for Treating Relapsed or Hard-to-Treat Multiple Myeloma — AstraZeneca
• BCMA Bispecific Antibody Therapy for Patients with Multiple Myeloma After CAR T-Cell Therapy Relapse — Medical College of Wisconsin
• Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone Versus Bortezomib with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Bendamustine, Pomalidomide, and Dexamethasone for Treating Relapsed or Refractory Multiple Myeloma — Cristina Gasparetto
• Study on Using PD-1 Blockade with Dendritic Cell/Myeloma Vaccines After Stem Cell Transplant for Multiple Myeloma — Beth Israel Deaconess Medical Center
• Study on Bortezomib, Isatuximab, Cyclophosphamide, and Dexamethasone for Multiple Myeloma Patients Eligible for Transplant — Medical College of Wisconsin
• Study on CAR-PRISM: Precision Intervention for High-Risk Smoldering Myeloma — Dana-Farber Cancer Institute
• Carfilzomib Treatment for Patients with Relapsed and Refractory Multiple Myeloma — Amgen
• Study on Carfilzomib, Iberdomide, and Dexamethasone for Transplant Eligible Multiple Myeloma — Hackensack Meridian Health
• COMbination Regimens in MM Post AHCT to ElimiNate MRD Utilizing IbERdomide — University of Alabama at Birmingham
• Combination Therapy with Mirdametinib and Sirolimus for Treating RAS Mutated Relapsed Refractory Multiple Myeloma — National Cancer Institute (NCI)
• Combination Treatment Approaches for High-Risk Multiple Myeloma: REACH Trial — Mayo Clinic

Looking for a program not shown above? Search the full catalog for “Multiple Myeloma” to see every match including additional filters.